Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-06-13Clinical Trial Update: Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma [Phase 1]
Phase 1 clinical trial evaluating C402-CD19-CAR for relapsed or refractory B-cell lymphomas is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-06-12Clinical Trial Update: Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating dose-adjusted EPOCH chemotherapy plus Rituximab in previously untreated aggressive non-Hodgkin lymphoma has complet…
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: The Role of Surgical Resection AND Stereotactic Radiosurgery in Primary Central Nervous System -Diffuse Large B Cell Lymphoma
This completed clinical trial investigates the potential role of surgical resection and stereotactic radiosurgery in treating primary centra…
-
CLINICAL_TRIALS trial_result · 2025-06-10Clinical Trial Update: Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial of selinexor in combination with ibrutinib for relapsed or refractory chronic lymphocytic leukemia and aggressive non-Hodgkin …
-
CLINICAL_TRIALS other · 2025-06-10Clinical Trial Update: Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL [Phase 2]
Phase 2 trial evaluating a triplet combination of glofitamab, polatuzumab vedotin, and zanubrutinib as first-line therapy in elderly patient…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-06-09Clinical Trial Update: A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL [Phase 1, Phase 2]
Phase 1/2 study of ATG-010 with lenalidomide and rituximab in adults with diffuse large B-cell lymphoma and indolent non-Hodgkin lymphoma ha…
-
CLINICAL_TRIALS research · 2025-06-08Clinical Trial Update: Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma [Phase 2]
This clinical trial update describes a Phase 2 study at the University of Chicago assessing pembrolizumab plus chemotherapy for untreated B-…
-
CLINICAL_TRIALS research · 2025-06-06Clinical Trial Update: Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
A clinical trial is investigating the effectiveness and safety of the CAR-T therapy tisagenlecleucel in Brazilian patients with B-lymphocyte…
-
CLINICAL_TRIALS trial_result · 2025-06-06Clinical Trial Update: Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL [Phase 2]
Phase 2 trial evaluating HMPL-760 plus R-GemOx versus placebo plus R-GemOx in relapsed/refractory diffuse large B-cell lymphoma; the study i…
-
CLINICAL_TRIALS research · 2025-06-05Clinical Trial Update: Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation [Phase 2]
This Phase 2 trial investigates HPV vaccination in recipients of allogeneic stem cell transplantation and is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-06-04Clinical Trial Update: Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation [Phase 2]
Phase 2 trial comparing three GVHD prophylaxis regimens in nonmyeloablative or reduced-intensity conditioning unrelated donor transplantatio…
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 1]
Phase 1 trial evaluating zanubrutinib in combination with lenalidomide, with or without rituximab, in relapsed/refractory diffuse large B-ce…
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL
This is an AstraZeneca-sponsored Brazilian clinical trial update for Diffuse Large B Cell Lymphoma (BRA-DLBCL) with the study status listed …
-
CLINICAL_TRIALS trial_result · 2025-05-21Clinical Trial Update: Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy [Phase 2]
Phase 2 clinical trial update for glofitamab in relapsed or refractory diffuse large B-cell lymphoma after CD19 CAR-T therapy; the study is …
-
CLINICAL_TRIALS trial_result · 2025-05-16Clinical Trial Update: Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating dendritic cell therapy with cryosurgery and pembrolizumab in various Non-Hodgkin lymphoma subtypes, w…
-
CLINICAL_TRIALS trial_result · 2025-05-15Clinical Trial Update: A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma [Phase 2]
A Phase 2 study of Firi-cel for relapsed/refractory diffuse large B-cell lymphoma has terminated; sponsor CARGO Therapeutics provided the st…
-
CLINICAL_TRIALS research · 2025-05-15Clinical Trial Update: A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas [Phase 1, Phase 2]
Clinical trial update for Tulmimetostat DZR123 (CPI-0209) in adults with advanced solid tumors and various lymphomas. The study is in Phase …
-
CLINICAL_TRIALS trial_result · 2025-05-14Clinical Trial Update: Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A phase 1/2 trial evaluated a conditioning regimen incorporating venetoclax, carmustine, etoposide, cytarabine, and melphalan before stem ce…
-
CLINICAL_TRIALS research · 2025-05-14Clinical Trial Update: GVM±R in Patients With Relapsed or Refractory Aggressive NHL. [Phase 2]
Phase 2 clinical trial update for GVM±R in adults with relapsed or refractory aggressive non-Hodgkin lymphoma, including Peripheral T-cell l…
-
CLINICAL_TRIALS research · 2025-05-14Clinical Trial Update: R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating the Rituximab-based R-CMOP regimen in newly diagnosed diffuse large B-cell lymphoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-05-13Clinical Trial Update: CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma [Phase 1, Phase 2]
This clinical trial update reports a Phase 1/2 study of CNCT19 CAR-T therapy in patients with relapsed or refractory diffuse large B-cell ly…
-
CLINICAL_TRIALS research · 2025-05-13Clinical Trial Update: Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study of PL001, a CD19 CAR-T cell therapy, for relapsed or refractory B-cell lymphoma. The …
-
CLINICAL_TRIALS research · 2025-05-13Clinical Trial Update: Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
This clinical trial registry entry describes a long-term follow-up study of a lentiviral-based gene-edited immune cell therapy for several B…
-
CLINICAL_TRIALS trial_result · 2025-05-11Clinical Trial Update: A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma [Phase 1]
Epizyme's Phase 1 study of EZM0414 (IPN60210) in relapsed/refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma …
-
CLINICAL_TRIALS withdrawal · 2025-05-06Clinical Trial Update: PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL [Phase 1]
Phase 1 trial evaluating PD-1, LAG-3, and TIM-3 checkpoint blockade for diffuse large B-cell lymphoma has been withdrawn.